Related Experiment Video
Updated: Jun 16, 2026
09:39
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
Published on: February 7, 2021
A novel transdermal honokiol formulation based on Pluronic F127 copolymer
XiuLing Zheng1, XiuHong Wang, MaLing Gou
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, PR China.
Drug Delivery
|February 24, 2010
Summary
This study presents a novel transdermal delivery system for hydrophobic honokiol using Pluronic F127 micelles and a thermosensitive hydrogel. The system enables sustained release and effective skin permeation of honokiol.
Area of Science:
- Materials Science
- Pharmaceutical Sciences
- Biotechnology
Background:
- Hydrophobic drugs like honokiol pose challenges for effective transdermal delivery.
- Developing advanced drug delivery systems is crucial for enhancing therapeutic efficacy.
Purpose of the Study:
- To develop and characterize a novel hydrophobic honokiol transdermal delivery system.
- To evaluate the in vitro release and permeation characteristics of honokiol from the developed system.
Main Methods:
- Honokiol was loaded into Pluronic F127 micelles via ultrasound-assisted dissolution.
- The micelles were incorporated into a thermosensitive F127 hydrogel to create a bioadhesive composite system.
- Characterization included particle size, drug loading, encapsulation efficiency, sol-gel transitions, in vitro release, and in vitro permeation studies.
Main Results:
- The developed system demonstrated controlled particle size, drug loading, and encapsulation efficiency.
- The composite system exhibited sustained in vitro release of honokiol.
- In vitro permeation studies confirmed effective percutaneous absorption of honokiol.
Conclusions:
- The novel Pluronic F127 micelle-hydrogel composite system is effective for transdermal delivery of hydrophobic honokiol.
- This system shows significant potential for the transdermal application of hydrophobic drugs.
Related Concept Videos
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...